• 1
    Yap KL, Ada GL, McKenzie IFC. Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus. Nature 1978; 273: 238239.
  • 2
    Zinkernagel RM, Haenseler E, Leist T, Cerny A, Hengartner H, Althage A. T cell-mediated hepatitis in mice infected with lymphocytic choriomeningitis virus. Liver cell destruction by H-2 class I-restricted virus-specific cytotoxic T cells as a physiological correlate of the 51Cr-release assay? J Exp Med 1986; 164: 10751092.
  • 3
    Kita H, Moriyama T, Kaneko T, Harase I, Nomura M, Miura H, Nakamura I, et al. HLA B44-restricted cytotoxic T lymphocytes recognizing an epitope on hepatitis C virus nucleocapsid protein. Hepatology 1993; 18: 10391044.
  • 4
    Koziel MJ, Dudley D, Wong JT, Dienstag J, Houghton M, Ralston R, Walker BD. Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J Immunol 1992; 149: 33393344.
  • 5
    Genesca J, Esteban JT, Alter HJ. Blood-borne non-A, non-B hepatitis: hepatitis C. Semin Liver Dis 1991; 11: 147164.
  • 6
    Hino K, Sainokami S, Shimoda K, Iino S, Wang Y, Okamoto H, Miyakawa Y, et al. Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C. J Med Virol 1994; 42: 299305.
  • 7
    Kita H, Hiroishi K, Moriyama T, Kaneko T, Ohnishi S, Yazaki Y, Imawari M. A minimal and optimal cytotoxic T-cell epitope within hepatitis C virus nucleoprotein. J Gen Virol 1995; 76: 31893193.
  • 8
    Gomez A, Bourgault I, Gomard E, Picard F, Levy J-P. Role of different lymphocyte subsets in human anti-viral T cell cultures. Cell Immunol 1989; 118: 312327.
  • 9
    Hill AB, Müllbacher A, Blanden RV. Ir1 genes, peripheral cross-tolerance and immunodominance in MHC class I-restricted T-cell responses: an old quagmire revisited. Immunol Rev 1993; 133: 7591.
  • 10
    Koziel MJ, Dudley D, Afdhal N, Grakoui A, Rice CM, Choo Q-L, Houghton M, et al. HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release. J Clin Invest 1995; 96: 23111321.
  • 11
    Khanna R, Burrows SR, Kurilla MG, Jacob CA, Misko IS, Sculley TB, Kieff E, et al. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J Exp Med 1992; 176: 169176.
  • 12
    Chan S-W, McOmich F, Holmes EC, Dow B, Peutherer JF, Follett E, Yap PL, et al. Analysis of a new hepatitis C virus type and its phylogenetic relationship to existing variants. J Gen Virol 1992; 73: 11311141.
  • 13
    Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, Tanaka T, et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 1992; 73: 673679.
  • 14
    Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 15131520.
  • 15
    Weiner AJ, Christopherson C, Hall JE, Bonino F, Saracco G, Brunetto MR, Crawford K, et al. Sequence variation in hepatitis C viral isolates. J Hepatol 1991; 13 (suppl4): S6S14.
  • 16
    Koziel MJ, Dudley D, Afdhal N, Choo Q-L, Houghton M, Ralston R, Walker BD. Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV. J Virol 1993; 67: 75227532.
  • 17
    Rammensee H-G, Friede T, Stevanovic S. MHC ligands and peptide motifs: first listing. Immunogenetics 1995; 41: 178228.
  • 18
    Fleischhauer K, Avila D, Vilbois F, Traversari C, Bordignon C, Wallny H-J. Characterization of natural peptide ligands for HLA-B*4402 and -B*4403: implications for peptide involvement in allorecognition of a single amino acid change in the HLA-B44 heavy chain. Tissue Antigens 1994; 44: 311317.
  • 19
    Yao Z, Keller E, Scholz S, McNicholas A, Volgger A, Albert ED. Identification of two major HLA-B44 subtypes and a novel B44 sequence (B*4404). Oligotyping and solid phase sequencing of polymerase chain reaction products. Hum Immunol 1995; 42: 5460.
  • 20
    Akahane Y, Kojima M, Sugai Y, Sakamoto M, Miyazaki Y, Tanaka T, Tsuda F, et al. Hepatitis C virus infection in spouses of patients with type C chronic liver disease. Ann Intern Med 1994; 120: 748752.
  • 21
    Tsubota H, Lord CI, Watkins DI, Morimoto C, Letvin NL. A cytotoxic T lymphocyte inhibits acquired immunodeficiency syndrome virus replication in peripheral blood lymphocytes. J Exp Med 1989; 169: 14211434.
  • 22
    Kita H, Moriyama T, Kaneko T, Okamoto H, Hiroishi K, Ohnishi S, Imawari M. HLA B44-restricted cytotoxic T lymphocyte responses to the pep-tides of HCV nucleoprotein residues 81–100 in patients with chronic hepatitis C. J Gastroenterol 1995; 30: 809812.
  • 23
    Minutello MA, Pileri P, Unutmaz D, Censini S, Kuo G, Houghton M, Brunetto MR, et al. Compartmentalization of T lymphocytes to the site of disease: intrahepatic CD4+ T cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis C. J Exp Med 1993; 178: 1725.
  • 24
    Moskophidis D, Lechner F, Pircher H, Zinkernagel RM. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 1993; 362: 758761.
  • 25
    Tekolf WA, Biddison WE, Aster RD, Shaw S. Two subgroups of HLA Bw44 defined by cell-mediated lympholysis that differ in Bw44 expression on platelets and in patterns of genetic linkage disequilibrium. J Immunol 1982: 14741478.
  • 26
    Ohnishi H. Typing of HLA class I alloantigen suballeles with PCR-RFLP method. Major Histocompatibility Gene Complex and Immune Response System 1994; 1: 4344 (in Japanese).
  • 27
    Koup RA. Virus escape from CTL recognition. J Exp Med 1994; 180: 779782.
  • 28
    Ho DD, Moudgil T, Alam M. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med 1989; 321: 16211625.
  • 29
    Coombs RW, Collier AC, Allain J-P, Nikora B, Leuther M, Gjerset GF, Corey L. Plasma viremia in human immunodeficiency virus infection. N Engl J Med 1989; 321: 16261631.
  • 30
    Carmichael A, Jin X, Sissons P, Borysiewicz L. Quantitative analysis of the human immunodeficiency virus type 1 (HIV-l)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein Barr virus in late disease. J Exp Med 1993; 177: 249256.
  • 31
    Hagiwara H, Hayashi N, Mita E, Naito M, Kasahara A, Fusamoto H, Kamada T. Quantitation of hepatitis C virus RNA in serum of asymptomatic blood donors and patients with type C chronic liver disease. Hepatology 1993; 17: 545550.
  • 32
    Kato N, Yokosuka O, Hosoda K, Ito Y, Ohoto M, Omata M. Quantification of hepatitis C virus by competitive reverse transcription-polymerase chain reaction: increase of the virus in advanced liver disease. Hepatology 1993; 18: 1620.
  • 33
    Mita E, Hayashi N, Kanazawa Y, Hagiwara H, Ueda K, Kasahara A, Fusamoto H, et al. Hepatitis C virus genotype and RNA titer in the progression of type C chronic liver disease. J Hepatol 1994; 21: 468473.
  • 34
    Fong T-L, Shindo M, Feinstone SM, Hoofnagle JH, Di Bisceglie AM. Detection of replicative intermediates of hepatitis C viral RNA in liver and serum of patients with chronic hepatitis C. J Clin Invest 1991; 88: 10581060.
  • 35
    Müller HM, Pfaff E, Goeser T, Kallinowski B, Solbach C, Theilmann L. Peripheral blood leukocytes serve as a possible extrahepatic site for hepatitis C virus replication. J Gen Virol 1993; 74: 669676.
  • 36
    Ando K, Guidotti LG, Cerny A, Ishikawa T, Chisari FV. CTL access to tissue antigen is restricted in vivo. J Immunol 1994; 153: 482488.